Roivant Sciences Ltd. 传来重磅消息。其研发的Brepocitinib,在针对皮肌炎的治疗上,已提交新药申请(NDA)。公司预计,该药物有望在2026年9月底前获得批准,并正式推向市场。这无疑是一个关键节点,标志着这家生物制药公司,在自身免疫疾病领域的布局迈出了坚实一步。皮肌炎作为一种罕见的自身免疫性疾病,一直缺乏有效的治疗手段。Brepocitinib若能如期获批,将为患者带来新的希望。目前,市场正密切关注这一进展,并期待其最终结果。
Roivant Sciences Ltd. 传来重磅消息。其研发的Brepocitinib,在针对皮肌炎的治疗上,已提交新药申请(NDA)。公司预计,该药物有望在2026年9月底前获得批准,并正式推向市场。这无疑是一个关键节点,标志着这家生物制药公司,在自身免疫疾病领域的布局迈出了坚实一步。皮肌炎作为一种罕见的自身免疫性疾病,一直缺乏有效的治疗手段。Brepocitinib若能如期获批,将为患者带来新的希望。目前,市场正密切关注这一进展,并期待其最终结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.